- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02496884
Safety Study of DS-5565 for Treatment of Fibromyalgia Pain in Subjects With Chronic Kidney Disease
A Randomized, Double-blind, Placebo-controlled Safety Study of DS-5565 for Treatment of Pain Due to Fibromyalgia in Subjects With Chronic Kidney Disease
Study Overview
Detailed Description
The main objective of the trial is to determine the safety and tolerability of subjects with FM and moderate to severe renal dysfunction during 13 weeks of renally-adjusted dosing of DS-5565 compared to placebo, followed by a short-term (4-week) safety follow-up.
This trial is conducted in accordance with the ethical principles of Good Clinical Practice, according to the International Council for Harmonisation (ICH) Harmonised Tripartite Guidelines. An independent Data Safety Monitoring Board (DSMB) is created to further protect the rights, safety, and well-being of subjects who participate in this study by monitoring their progress and results. The independent DSMB is composed of qualified scientists who are not investigators in the study and not otherwise directly associated with the sponsor.
Additional protection is provided by special monitoring of liver enzyme elevations and liver dysfunction performed by a Hepatic Adjudication Committee (HAC), comprised of three qualified hepatologists who are not investigators in the study and not otherwise directly associated with the sponsor. The HAC completes assessments on an ongoing basis. Adjudication of hepatic events is based on evaluation of electronic case report forms (eCRFs) and source documents, as available, including but not limited to hospital discharge summaries, diagnostic imaging, histopathology, consultation, and laboratory reports.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Plovdiv, Bulgaria
-
Sevlievo, Bulgaria
-
Sofia, Bulgaria
-
Stara Zagora, Bulgaria
-
Varna, Bulgaria
-
-
-
-
-
Prague, Czechia
-
Ricany, Czechia
-
-
-
-
-
Budapest, Hungary
-
Nyiregyhaza, Hungary
-
-
-
-
-
Elblag, Poland
-
Kraków, Poland
-
-
-
-
-
Cluj-napoca, Romania
-
-
-
-
-
Johannesburg, South Africa
-
Pretoria, South Africa
-
-
-
-
-
Barcelona, Spain
-
Santiago de Compostela, Spain
-
Valencia, Spain
-
-
-
-
Arizona
-
Phoenix, Arizona, United States, 85018
-
-
California
-
Colton, California, United States, 92324
-
Los Angeles, California, United States, 90033
-
Santa Ana, California, United States, 92705
-
-
Colorado
-
Colorado Springs, Colorado, United States, 80918
-
-
Florida
-
Brooksville, Florida, United States, 34601
-
DeBary, Florida, United States, 32713
-
Hialeah, Florida, United States, 33013
-
Kissimmee, Florida, United States, 34744
-
Miami, Florida, United States, 33144
-
-
Michigan
-
Grand Blanc, Michigan, United States, 48439
-
-
North Carolina
-
High Point, North Carolina, United States, 27262
-
-
Ohio
-
Cincinnati, Ohio, United States, 45224
-
-
Pennsylvania
-
Wyomissing, Pennsylvania, United States, 19610
-
-
South Carolina
-
Greer, South Carolina, United States, 29651
-
-
South Dakota
-
Rapid City, South Dakota, United States, 57702
-
-
Tennessee
-
Knoxville, Tennessee, United States, 37919
-
-
Texas
-
Houston, Texas, United States, 77098
-
Plano, Texas, United States, 75093
-
-
Washington
-
Bellevue, Washington, United States, 98007
-
-
West Virginia
-
Charleston, West Virginia, United States, 25304
-
Morgantown, West Virginia, United States, 26505
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Abbreviations: alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine clearance [(CrCL) determined by the central laboratory using the Cockcroft-Gault equation], upper limit of normal (ULN), Columbia-Suicide Severity Rating Scale (C-SSRS)
Inclusion Criteria:
- Age ≥ 18 years
- Able to give written informed consent
- Able to complete patient-reported questionnaires per the Investigator's judgment
- Estimated CrCl between 15-59 mL/min from serum creatinine by the central laboratory using the Cockcroft-Gault equation
Fibromyalgia meeting American College of Rheumatology criteria for FM:
- Widespread pain index (WPI) ≥ 7 and symptom severity (SS) scale score ≥ 5 or WPI 3 to 6 and SS scale score ≥ 9,
- Pain in at least 11 of 18 specific tender point sites,
- Symptoms have been present at a similar level for at least 3 months, and
- The subject does not have a disorder that would otherwise explain the pain
- Average Daily Pain Score of ≥ 4 on the 11-point numeric rating scale (NRS) over the 7 days prior to randomization (based on completion of at least 4 daily pain assessments during the 7-day baseline period prior to randomization)
- Women of child bearing potential (WOCBP) must be using adequate methods of contraception to avoid pregnancy during the study and for 4 weeks after study completion.
Exclusion Criteria:
- Need for ongoing use of concomitant chronic pain medications or any new non-pharmacological pain management techniques that may confound assessments of efficacy and/or safety, including neurolytic treatments (destruction of nerves by chemicals, heat, cold) or surgery, intrathecal pumps, spinal cord stimulators or psychological support within the previous year. Also excluded: topical capsaicin within 6 months; or systemic corticosteroids within 3 months of baseline period.
- Unable to undergo pre-study washout of prohibited concomitant medications
- Subjects with recent history (i.e., within 1 year prior to screening) of alcohol abuse or illicit drug use (cocaine, heroin, marijuana [including medical, prescribed], etc.)
- Use of any selective serotonin reuptake inhibitor (SSRI), unless the subject has been on a stable dose for ≥ 90 days prior to screening and is not anticipated to need any dose adjustment during the course of the study
- Subjects with severe or uncontrolled depression that, in the judgment of the Investigator, makes the subject inappropriate for entry into the study
- Significant neurological or psychiatric disorder unrelated to neuropathic pain
- Other severe pain (eg, sciatica, rheumatoid arthritis) that might impair the assessment of neuropathic pain
- CrCl ≥ 60 mL/min estimated from serum creatinine by the central laboratory using the Cockcroft-Gault equation.
- Subjects who are on hemodialysis or who require hemodialysis before the follow-up assessment; acute renal failure; history of kidney transplant
- Any history of a malignancy other than basal cell carcinoma within the past 5 years
- Clinically significant unstable neurologic, ophthalmologic, hepatobiliary, respiratory, or hematologic illness or unstable cardiovascular disease (eg, severe hypotension, uncontrolled cardiac arrhythmia, or myocardial infarction) within 12 months prior to screening
- Pregnancy or breast feeding or intent to become pregnant during the study period
- Known hypersensitivity to α2δ ligands or other components of the study medications. Note: Prior exposure to DS-5565 is allowed, as long as hypersensitivity to DS-5565 was not observed.
- Clinically significant ECG abnormalities at the Screening Visit
- Subjects who are at risk of suicide, as defined by their responses to the C-SSRS or in the opinion of the Investigator. Note: Subjects answering "yes" to any of the questions about active suicidal ideation/intent/behaviors that occurred within the past 12 months must be excluded (C-SSRS Suicide Ideation section - Questions 3, 4, or 5; C-SSRS Suicidal Behavior section - any of the suicide behaviors questions). Such subjects should be referred immediately to a mental health professional for appropriate evaluation.
- Subjects who are unlikely to comply with the protocol (eg, uncooperative attitude, inability to return for subsequent visits, and/or otherwise considered by the Investigator to be unlikely to complete the study)
- Subject is currently enrolled in, or it has been fewer than 30 days since ending, another investigational device or drug study or is receiving another investigational agent.
- Subjects who are employees or immediate family of employees of the study site, Sponsor, or contract research organization (CRO)
Screening laboratory values outside the limits listed in the table below:
- Hematology
- Hemoglobin < 8 g/dL
- Platelet count < 100,000/mm3
- Absolute neutrophil count < 1,500/mm3
- Blood chemistry
- AST > 2.0 × ULN
- ALT > 2.0 × ULN
- Alkaline phosphatase > 1.5 × ULN
- Total bilirubin > 1.2 × ULN (If a subject has total bilirubin >ULN: unconjugated and conjugated bilirubin fractions should be analyzed and only subject documented to have Gilbert's syndrome may be enrolled)
- Creatine kinase > 3.0 × ULN
- Calculated CrCl ≥ 60 mL/min
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: M-CKD DS-5565 7.5 mg BID
Patients with moderate chronic kidney disease (M-CKD) randomized to receive DS-5565 BID during the treatment period.
|
DS-5565 7.5 mg tablet for oral use
Other Names:
|
Experimental: S-CKD DS-5565 7.5 mg QD
Fibromyalgia patients with severe chronic kidney disease (S-CKD) randomized to receive a DS-5565 7.5 mg tablet once per day (QD), and a placebo tablet (no drug) QD, for a total of 7.5 mg DS-5565
|
DS-5565 7.5 mg tablet for oral use
Other Names:
Placebo tablet for oral use to match DS-5565 7.5 mg tablet
Other Names:
|
Placebo Comparator: M-CKD Placebo
Patients with M-CKD randomized to receive placebo twice daily (BID) during the treatment period.
|
Placebo tablet for oral use to match DS-5565 7.5 mg tablet
Other Names:
|
Placebo Comparator: S-CKD Placebo
Patients with S-CKD randomized to receive placebo once daily (QD) during the treatment period.
|
Placebo tablet for oral use to match DS-5565 7.5 mg tablet
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants Experiencing a Treatment Emergent Adverse Event (TEAE)
Time Frame: Baseline up to 30 days after last dose, up to 25 months
|
A TEAE is any adverse event that emerges on or after the first dosing of double blind study medication and during study treatment up to 4 weeks after the last dose of double blind study medication (having been absent prior to treatment) or worsens relative to the pre-double blind treatment state. Relationship of TEAEs to study drug is assessed by the investigator. Clinically significant changes from baseline in clinical laboratory evaluations, neurological examinations, and electrocardiograms are reported as TEAEs. |
Baseline up to 30 days after last dose, up to 25 months
|
Patients Answering Yes to Any Question on the Columbia-Suicide Severity Rating Scale (C-SSRS)
Time Frame: Screening up to Week 13 postdose
|
The C-SSRS is described as a scale developed at Columbia University that has 2-6 questions each in categories of Suicidal Ideation, Intensity of Ideation, Suicidal Behavior, and Actual Attempts.
Four constructs were measured.
Severity of Suicidal ideation is rated on a 5-point ordinal scale.
Intensity of ideation is comprised of 5 items (frequency, duration, controllability, deterrents, and reason for ideation), each rated on a 5-point ordinal scale.
Suicidal behavior is rated on a nominal scale that includes actual, aborted, and interrupted attempts; preparatory behavior; and non-suicidal self-injurious behavior.
Lethality, assesses actual attempts; actual lethality is rated on a 6-point ordinal scale, and if actual lethality is 0, potential lethality of attempts is rated on a 3-point ordinal scale.The higher the C-SSRS score, the higher the suicide risk (ie.
worse outcome).
|
Screening up to Week 13 postdose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Weekly Average of Individual Daily Pain Scores (ADPS)
Time Frame: Baseline, Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 7, Week 8, Week 9, Week 10, Week 11, Week 12, and Week 13 postdose
|
Each day participants will rate their worst pain over the last 24 hours on a scale from 0-10, where 0=no pain and 10=worst pain imaginable.
Each week individual pain scores will be averaged, and the mean weekly score for the treatment group will be calculated.
Higher ADPS scores indicate worse outcome.
|
Baseline, Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 7, Week 8, Week 9, Week 10, Week 11, Week 12, and Week 13 postdose
|
Number of Participants With Different Scale Ranges of the Patient Global Impression of Change (PGIC) Scale at Week 13
Time Frame: Week 13 postdose
|
The PGIC is a validated outcome measure for treatment of pain in the acute pain setting.
At the end of treatment, participants will rate their overall status on a scale of 1-7, where 1=very much improved and 7=very much worse using the standard PGIC questionnaire.
Higher scores indicate worse outcome.
|
Week 13 postdose
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DS5565-A-U307
- 2014-003972-21 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- Study Protocol
- Statistical Analysis Plan (SAP)
- Clinical Study Report (CSR)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fibromyalgia
-
University of AberdeenCompletedFibromyalgia | Fibromyalgia, Primary | Fibromyalgia, SecondaryUnited Kingdom
-
Eli Lilly and CompanyCompletedFibromyalgia, Primary | Fibromyalgia, SecondaryMexico
-
Rasmia ElgoharyNot yet recruiting
-
Tel-Aviv Sourasky Medical CenterCompletedFibromyalgia (FM)Israel
-
Yousra Hisham Abdel FattahCompletedFibromyalgia, PrimaryEgypt
-
Forest LaboratoriesCypress Bioscience, Inc.TerminatedPrimary FibromyalgiaUnited States
-
Universidade Federal do Rio Grande do NorteCompleted
-
Tonix Pharmaceuticals, Inc.CompletedPrimary FibromyalgiaUnited States
-
Tonix Pharmaceuticals, Inc.CompletedPrimary FibromyalgiaUnited States
-
University of ManitobaCompleted
Clinical Trials on DS-5565
-
Daiichi Sankyo Co., Ltd.CMIC Co, Ltd. JapanCompletedDiabetic Peripheral Neuropathic Pain | Post-herpetic NeuralgiaJapan
-
Daiichi Sankyo Co., Ltd.Quintiles, Inc.; SRL Medisearch Inc.Completed
-
Daiichi Sankyo, Inc.CompletedPain Associated With FibromyalgiaPoland, Ukraine, Germany, Spain, United States, Austria, Portugal, Slovenia, Bulgaria, Romania, Serbia, Canada, Australia, Estonia, Russian Federation, New Zealand, Hungary, Denmark, Lithuania, Slovakia, South Africa, Latvia, Finland, Norwa... and more
-
Daiichi Sankyo Co., Ltd.CompletedDiabetic Peripheral Neuropathic PainChina
-
Daiichi Sankyo Co., Ltd.Quintiles, Inc.; CMIC Co, Ltd. Japan; Quintiles Malaysia Sdn. Bhd.CompletedDiabetic Peripheral Neuropathic PainJapan
-
Daiichi Sankyo Co., Ltd.CompletedCentral Neuropathic PainJapan, Korea, Republic of, Taiwan
-
Daiichi Sankyo, Inc.Syneos HealthCompletedPain Associated With FibromyalgiaUnited Kingdom, United States, Bulgaria, Romania, New Zealand, Australia, Russian Federation, Hungary, Slovakia, India, Latvia, Estonia
-
Daiichi Sankyo, Inc.Syneos HealthCompletedPain Associated With FibromyalgiaUnited States, France, Germany, Serbia, Netherlands, Denmark, Sweden, Canada, Norway, Finland, Czechia
-
Daiichi Sankyo, Inc.CompletedDiabetic Peripheral NeuropathyUnited States
-
Ludwig Institute for Cancer ResearchDaiichi Sankyo Co., Ltd.; Austin HealthCompletedMalignant Solid Tumor | Metastatic EphA2 Positive CancerAustralia